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Abstract
© 2018  Nurkhametova,  Kudryavtsev,  Khayrutdinova,  Serebryakova,  Altunbaev,  Malm  and
Giniatullin. Objectives: Immune responses in migraine are poorly characterized, yet implicated
in the disease pathogenesis. This study was carried out to characterize purinergic profiles of T-
cells in patients with episodic migraine without aura (MWoA) to provide mechanistic evidence
for ATP and adenosine involvement in modulation of immune regulation in migraine. Methods:
Peripheral blood samples were obtained from patients with migraine (n = 16) and age-matched
control subjects (n = 21). Subsets of T-cells were identified by flow cytometry based on specific
membrane  markers.  Results:  Migraine  patients  showed  reduced  total  T-cell  counts  in  the
peripheral  blood.  Whereas  the  total  number  of  CD3+CD4+,  CD3+CD8+,  or  regulatory  T
lymphocytes  (Treg)  was  not  changed,  the  proportion  of  Treg  CD45R0+CD62L–  and
CD45R0–CD62L– cells was increased. Interestingly, in migraine, less Treg cells expressed CD39
and CD73 suggesting disrupted ATP breakdown to adenosine. The negative correlations were
observed between the duration of migraine and the relative number of CD73+CD39– Tregs and
total number of CD73-positive CD45R0+CD62L+ Tregs. Conclusion: Obtained data indicate that
T-cell populations are altered in episodic migraine and suggest the involvement of Tregs in the
pathophysiology of this disorder. Reduced expression of CD39 and CD73 suggests promotion of
ATP-dependent  pro-inflammatory  and  reduction  of  adenosine-mediated  anti-inflammatory
mechanisms  in  migraine.
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